Follow us on
KEW announces Characterization of biomarkers to immune checkpoint blockade therapy across solid tumors at ASCO SITC. January 26, 2018.
Immune checkpoint blockade (ICB) therapy has been effective patients with solid tumors. Currently, tumor expression of programmed death-ligand 1 (PD-L1) is clinically used as a biomarker of predicted response to ICBs in non-small cell lung cancer (NSCLC). However, across solid tumors, only a subset of patients benefit from ICBs, so there is need to identify other biomarkers to predict response to ICB. We investigated the use of large panel next generation sequencing (NGS) to characterize biomarkers to ICBs across solid tumors. Read Article> https://meetinglibrary.asco.org/record/156658/abstract
KEW announces Characterization of tumor mutation burden (TMB) and microsatellite instability (MSI) interplay for gastroesophageal adenocarcinoma (GA) and colorectal carcinoma (CRC) at ASCO SITC, January 26, 2018.
Tumor genomic instability is positively correlated with immunotherapy response. It confers different tumor phenotypes, including high TMB (TMB-H) and high MSI (MSI-H). Recently the US Food and Drug Administration approved MSI-H phenotype as a biomarker for immunotherapy, highlighting its importance, but also bringing up the question of how TMB as another promising biomarker is going to add value in the field. Here, we characterized TMB and MSI profiles to better understand the potential TMB contribution and identify genomic markers for it. Read Article > https://meetinglibrary.asco.org/record/156675/abstract
KEW Announces Publication of Analytical Validation Data 06/02/2017
The study demonstrates KEW’s orthogonal validation of somatic genomic variants in solid tumors characterized by CANCERPLEX® with specificity and sensitivity >99.5%. Overall clinical actionability was 93% in...Read Article >
Clinical application of a cancer genomic profiling assay to guide precision medicine decisions
KEW, Inc. Receives 2016 Best of Cambridge Award
KEW and the National Foundation for Cancer Research Announce Collaboration to Increase Awareness of CANCERPLEX®
KEW Announces 2016 ASCO Abstract
KEW Announces Name Change and Receives College of American Pathologists (CAP) Accreditation
KEW’s CancerPlex® molecular diagnostic test made available for cancer patients in EU through myTomorrows platform
KEW Group and Denka Collaborate on a Study to Identify the Benefits of CancerPlex® NGS Testing In Japanese Cancer Patients 10/20/2015
Tom Miller Joins KEW Group as Independent Director
Genomic Expression and KEW Group to Collaborate
KEW Group Raises $16.8 Million in Series B Financing
KEW Group Inc. Announces Completion of Private Financing Round
KEW Group Launches CancerPlex® Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists
Size does matter. Provide the level of care you would want for your own loved ones.
AACR Annual Meeting 2017 – Abstract: Genomic Profiling of the Tumors Harboring Activating EGFR Mutations
EGFR is a receptor tyrosine kinase of the HER/ERBB family and an oncogenic driver, especially for NSCLC, HNSCC and CRC. EGFR targeted therapies have been successfully used for treating cancer patients harboring activating EGFR mutations. However a main challenge is acquired drug resistance due to mutations or alternative signaling. While developing next generation drugs is…
840 Memorial Drive, 4th Floor Cambridge, MA 02139